Executive Summary
Background

Health care and medication costs
In 2010, nearly $2.6 trillion was spent on health care in the U.S., an average of $8,402 per person, with a staggering 12 percent of these total expenditures paid by consumers directly [4] . At 3.9 percent a year, the rate of growth in health care costs continues to outstrip the overall growth of the economy, increasing the costs for consumers, employers and government. A 2012 Kaiser Tracking Poll found that more than half of Americans said their families cut back on medical care due to cost concerns in the previous year [5] .
Prescription drug expenses are widely reported to be a tenth of overall health care expenses, or about $260 billion in 2012. However, that share rises to 17 percent if prescription drugs used in physicians' offices, hospitals, clinics and other settings, as well as over-the-counter and non-prescription drugs, are included [6] .
In 2010, consumers paid about 20 percent of the cost of prescription drug expenses, significantly above the average 12 percent contribution for other health care services [7] . Those who incurred any prescription drug expenses (about two-thirds of Americans) paid on average $1,302 per person [8] . However, those families and individuals that used more than the average number of prescription drugs-such as seniors and people with chronic diseases-were confronted with much higher than average costs, and those who were uninsured were forced to either pay the full cost or go without their medication. For example, uninsured non-elderly adults (aged 18-64) surveyed in 2012 were more than twice as likely as those with insurance to say that they could not fill a prescription or that they had skipped doses [5] .
An individual patient's cost burden for prescription drugs is dependent upon a number of inter-related factors: whether they have insurance, how their insurer structures "costsharing" or out-of-pocket costs for prescriptions, the number of drugs they are prescribed, which drugs are selected by their prescriber, and the actual retail costs of those drugs.
The number of drugs prescribed in the U.S. has climbed steadily for decades, with outpatient prescriptions rising from 1 billion in 1970 to more than 4.1 billion in 2008. The sharpest rise occurred from 1997 to 2008, which may be due to several factors, including the development of new drugs for previously untreatable conditions such as HIV, expanded treatment guidelines for certain conditions, such as high cholesterol, and promotional marketing to patients and physicians. For instance, direct-to-consumer advertising (DTCA) rose dramatically after FDA relaxed advertising regulations in 1997 [6] . In 2008, the industry spent $4.4 billion on DTCA [9] .
Advertising and promotions to physicians have also risen dramatically; from $3.5 billion in 1996 to $6.6 billion in 2009 (this excludes samples, valued at $15.9 billion when last documented in 2004). Some investigators estimate the total promotional spending by industry to be much higher, at $57.5 billion per year [10] . Marketing has an effect not only on the volume of prescriptions written, but also the types of drugs prescribed, because industry promotes the newer, more expensive brand-name drugs and not older, better established drugs, which are mostly generic.
Finally, the average prescription price has increased from $22.06 in 1990 to $71.69 in 2008 , nearly twice what it would have been ($35.90) if the price had risen at the same rate as the consumer price index (CPI). Brand-name drugs are far more costly than generics, averaging $137.90 per brandname prescription vs. $35.22 for generics in 2008 [6] . As a result, while generics now account for 80 percent of prescriptions, they make up only 27 percent of total spending on prescriptions. [35] Burden of medication costs and its impact on adherence to treatment Medication adherence refers to the "extent to which the patient's action matches the agreed upon recommendations" and has come to be adopted as a less paternalistic term than medication compliance, or the "extent to which a person's behavior coincides with medical or health advice [11] ." While we use the term adherence in this paper, we note that an even more patient-centric concept, "concordance", has been recommended by some. Concordance suggests "that the work of the prescriber and patient in the consultation is a negotiation between equals and... [t] he aim is a therapeutic alliance between them..." [12] . As we discuss later, such shared decision making may be important to successful prescriber-patient communication about costs.
Lack of adherence to long-term pharmaceutical treatment regimens undermines the effectiveness of medical care. The World Health Organization found that adherence to longterm therapy for chronic illnesses in developed countries averaged just 50 percent, with even lower rates in developing countries. Solving the problems faced by patients in adhering to medication therapy means addressing a number of interrelated barriers, including "social and economic factors, the health care team/system, the characteristics of the disease, disease therapies and patient-related factors" [13] . The overall cost burden of medications can play an important part in whether patients can or will take medications they are 
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prescribed. Non-adherence with drug therapy is associated with many factors, including limited income, serious or chronic health conditions and/or the extent of cost shifting to patients through high co-pays or deductibles, formulary restrictions or outright caps on coverage [14] - [18] . Thus, for patients facing these challenges, the prescriber's selection of expensive brand-name drugs over low-cost generics can significantly reduce adherence to treatment.
Cost burdens are highest for patients without insurance. However, patients who are underinsured or are exposed to high levels of cost sharing can also struggle to adhere to treatment. Nearly all commercial health insurance is designed to facilitate the selection of lower cost, higher value medications through the use of policies such as tiered formularies with higher co-pays for brand-name drugs, prior authorization for brand-name drugs, or step therapy (beginning therapy with the lower-cost alternative). For patients with fewer health care needs, these policies can, with appropriate protections, facilitate the choice of evidence-based therapies. However, policies imposed by some insurers-benefit caps or limits on the number of medications allowed each month, etc.-can leave patients without coverage for needed prescriptions, leading to nonadherence and increased use of other health care services [18] , [19] .
A synthesis of 132 articles from 1985-2006 on the impact of changes in insurance benefit designs found that increases of 10 percent in patient costs were associated with a 2 percent to 6 percent decline in prescription drug use or expenditures. However, the impact of patient cost sharing varied by patient characteristics, such as income and clinical condition. Increased cost-sharing for chronically ill patients (such as those with congestive heart failure, lipid disorders, diabetes and schizophrenia) was associated with reduced use of medications and greater use of inpatient and emergency medical services [18] . In contrast, with reduced cost-sharing for selected chronic conditions, adherence to medication was found to improve by 3.1 percent, while overall health care costs were stabilized or declined [20] .
Prescriber-patient communication about medication costs
A 2011 Consumer Reports survey of primary care providers found that "non-compliance with advice or treatment recommendations" was the top complaint doctors had about their patients, and thirty-seven percent thought it negatively affected their ability to provide quality care "a lot" [25] . As the authors point out, however, patients face many challenges in following treatment recommendations. Indeed, in a subsequent survey of patients, Consumer Reports found that half of the consumers surveyed who took any prescription drug had faced difficulty affording their out-ofpocket costs. Yet most of these consumers did not feel comfortable discussing their difficulty affording medications with either their doctors (48 percent) or pharmacists (68 percent) [36] .
Despite the negative effect of medication cost burdens on patient adherence, most physicians know little about drug prices or differences in price among competing therapies. This limits physicians' ability to advise patients about drug costs and work with them to address affordability. Physicians report that patients are also frequently unaware of the costs of medications prescribed [1] , [2] , [17] , [21] . A substantial proportion of patients also report being uncomfortable discussing-with either their prescribing doctors or their pharmacists-their inability to afford medications [22] . Yet physicians, other prescribers, and pharmacists are the experts that patients should be able to rely upon to help them reduce their monthly out-of-pocket cost burden.
Given limited knowledge about drug costs by both providers and patients, it is not surprising that discussions between patients and prescribers about the costs of medications rarely occur. In one survey of general internists and their patients, only 35 percent of physicians and 15 percent of patients ever discussed patients' out of pocket costs [22] . Yet other research shows that physicians want to know more about costs, and both patients and physicians express a desire to engage with each other more frequently about out-of-pocket costs [1] , [2] , [24] .
Methods
We conducted a pilot study of primary care physicians to explore the factors affecting their communication with patients about drug prices and affordability. We also assessed the appeal and utility of a model web-based drug pricing resource to facilitate communication and enhance shared decision-making between providers and patients. The model drug pricing resource provided price comparisons between one group of widely prescribed medications (statins), at various pharmacies within specific ZIP codes, allowing prescribers to more clearly understand the cost impacts of their drug selection. 
Sample
Since studies have shown that most physicians rarely discuss drug costs or affordability with their patients, we selected a sample of primary care physicians who were more likely to engage frequently with patients. Our assumption was that, without this selection, the small size of the pilot study sample would yield too few physicians with interest or experience in addressing cost and affordability issues, and thus we would not be able to gather detailed information on the dynamics of these physician-patient communications about drug costs, or the potential utility of our model resource. We also selected physicians who were in practice less than twenty years, to mitigate the potential for variation based on age in our small sample.
We screened and selected primary care physicians who selfreported (1) a high level of concern for the cost of prescription medications prescribed for their patients and (2) that they work in practices with a preponderance of middle class and lower middle class/working poor patients who were not on Medicaid. 2 
Qualitative Telephone Interviews
Eight primary care physicians were screened and recruited for inclusion in the qualitative phase from a total of two hundred potential candidates randomly selected from MMRx's proprietary database of 10,000 primary care physicians.
Respondents were paid an incentive of $60 and participated in a one-on-one telephone interview of approximately 30 minutes in duration.
During each interview, a physician was given a link to two hypothetical Internet sites labeled 'Concept 1' and 'Concept 2', as shown in Figure 1 and Figure 2 respectively, that presented comparative drug price information. Following exposure, participants responded to questions regarding likely usage of the comparative price resource and the advantages it may offer in patient care. (See Appendix A for the Interview Protocol.)
Follow-Up Survey
Forty online surveys were completed by respondents over the course of five days. Respondents were again randomly recruited to participate from MMRx's PCP data base of 10,000 primary care physicians, using the screening criteria above. Approximately 6,000 contacts were made, and 219 physicians attempted to complete the survey. Of these, 13 dropped out for no particular reason and 179 did not meet the screening criteria because they:
• were in other specialties (36) • spent less than 50 percent of their time in clinical practice (3) • were in practice for more than 20 years (55) • were concerned with the cost of drugs prescribed only 1-7 on a 10 point scale (22) • were over quota for the region (5) Participants visited a web-based survey site. (See Appendix B.) During the course of the survey, respondents were presented links to two additional websites hosting variations of our model drug pricing resource. These were labeled 'Concept 1' and 'Concept 2', as shown in Figure 1 and Figure 2 respectively. Assume that these alternatives were chosen by an independent scientific advisory board, unaffiliated with any drug manufacturer, based on reviews of available studies." Restated, the model resource would provide the actual retail costs of brand-name and generic drugs, for all doses, at all pharmacies in a 20 mile radius, including the names and prices of lower-cost competing therapeutic alternatives, chosen based on unbiased scientific sources.
Concept
Concept 2 presented the same information, but replaced retail prices with out-of-pocket co-payments under Medicare Part D, in any instances where the copayment is less than the retail prices. The introductory text asked respondents to assume that the resource would have the same functionality as Concept 1 but also allow users to input the name of the patient's Medicare Part D plan to see the expected co-pay amount (see survey Q16, Appendix B, for full text).
Following exposure to the concepts, participants responded to questions regarding the features of this model resource, their interest in using it, and the potential advantages it may offer in patient care.
Results
Qualitative Interview results
The responses from the preliminary interviews provided additional insights into our two important themesprescriber-patient communication and burden of drug costs-as well as feedback about the resource. These data were used in the design of the quantitative survey.
The eight respondents interviewed were from North Carolina, New Jersey, California, New York, Massachusetts, and Florida and ranged in experience from 8 to 24 years in practice. Three of the physicians interviewed were female, five were male. Respondents reported approximately two-thirds of patients in their practice were fully insured, and all rated their concern about patients' ability to pay for prescription drugs as an 8 or higher on a 10-point scale, where 10 equals extremely concerned.
Prescriber-patient communication about medication costs
Interviewees noted that conversations about drug costs have become routine for physicians caring for both low-income and higher-income patients: 
Burden of medication costs and adherence to treatment
Physicians interviewed reported learning after the fact that affordability had been an issue, leading patients to take worrisome measures to reduce their cost burden. These include failing to fill prescriptions, or taking less than the prescribed dose, to stretch out their prescriptions. Additional time burdens on physicians and staff also resulted when the patient had to ask the pharmacy to call to replace a prescription the patient could not afford. Some physicians interviewed reported using the limited price information they have to inform patients about drug prices, or taking additional steps to gather more information. They also attempted to assist patients in a number of ways, including offering samples, prescribing longer supplies, prescribing combination products, writing for generics, or recommending discount programs at local retailers or pharmacies.
"We look for what's best for the patients. I will tell patients where to get the cheapest medications. I also have one of my employees call pharmacies and check prices." "We try to stick to the Target $4 list as much as we can, co-pay cards, supplement with samples." "Reps will give us a list of the cost of brand name products at local pharmacies."
Response to specific characteristics of the on-line resource and suggestions for its design After reviewing a description and screenshot serving as a representative sample of a model drug pricing resource, all participants responded favorably. They predicted that such a resource would be "very useful" for providers, their staff, and patients themselves: Some felt that the resource could impact cost, efficiency, and even adherence:
"Extremely efficient, cost effective, save on time, increase compliance because the patient will know the cost and will take the medicine."
Quantitative Survey Results
As described above, 40 online surveys were completed by primary care physicians. The characteristics of these respondents were:
• Primary Care Physician (n = 40) 
Prescriber-patient communication about medication costs
Respondents reported seeing an average of 30 patients a day in their practices, and discussing the cost of prescription medication with an average of 13 patients a day (43 percent). Total cumulative time spent on these discussions was estimated to be an average of 1 hour per day of physician and/or staff time. (Table 2) Half of the survey respondents found it relatively difficult to engage patients in discussions concerning the cost of the medications they prescribe. Fifty percent of respondents rated the difficulty as six or higher on a 10 point scale. At the same time, 50 percent of respondents found discussions of drug costs to be comparatively easier, rating the difficulty as a five or lower, yielding a bi-modal distribution. (Table 4) One open-ended question asked respondents how issues concerning the cost of medications, or their patients' abilities to afford or access their medications, are raised when such discussions do occur. Responses included: the physician asks patients if they can afford their medications (32.5 percent); asks patients if they have had any problems getting or taking their medications (17.5 percent); or asks patients if they have prescription drug coverage (7.5 percent). Respondents also report that patients bring up the issue about 30 percent of the time, often as a complaint about the cost of medication. (Table 5 ) Overall, it appears that both patients and physicians raise this issue directly and indirectly, but that physicians initiate these discussions in nearly twice as many different ways as their patients do.
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Physicians reported that they use many types of information to answer patient questions concerning the cost of medications. These include cost information from local pharmacies or pharmacists (30 percent), formulary information provided by insurers (20 percent), and cost information from drug company sales representatives (20 percent). Respondents gained cost information from government or other websites 10 percent of the time and from the Epocrates handheld app 10 percent of the time. (Table 6) Burden of medication costs and its impact on adherence to treatment Respondents reported encountering situations of nonadherence to treatment due to the cost of medication frequently-an average of 26 times per month patients had not filled a prescription and 28 times per month patients were taking less than the prescribed dose due to costs. (Table 3) In response to an open ended question about current strategies respondents are using to reduce the cost of medications for some or all of their patients, the top two strategies were prescribing generics (60 percent) and giving free samples to patients (40 percent). To a lesser extent respondents used drug company patient assistance programs (17.5 percent), coupons and rebates (17.5 percent), as well as similar cost reduction cards and vouchers. Five percent recommended that patients split pills and only 5 percent explicitly mentioned using the $4/$12 drug lists available at some pharmacies. (Table 7) Response to the model web-based drug pricing resource More than 80 percent of respondents had a positive response to the web-based drug pricing resource, with just one respondent having a negative response. (Table 8 ) Ninety percent said they would use the resource, and 35 percent thought they would use it frequently. (Table 11 ) On the whole, physicians predicted that using this resource would significantly reduce cost-related barriers to adherence. Eighty percent thought it would substantially (seven or higher on a 10 point scale) reduce how often patients failed to fill their prescriptions due to cost, and 70 percent predicted it would significantly reduce how often patients did not take their medications. (Table 14b , 14c) In addition, 90 percent of respondents predicted this resource would be moderately to extremely useful (seven or higher) in making it easier to engage with patients in a discussion of cost and affordability of medications. (Table 15 ) Respondents anticipated the resource would be used almost equally by physicians (with their patients), by staff or nurses, and by patients themselves. (Table 12 ) Furthermore, 90 percent of respondents stated that they would use it "often" to "frequently" (seven or higher, Table 11 ) and perhaps as much as ten times per day. (Table 13 ) The majority of respondents felt it had the potential to reduce the amount of time they spend addressing their patients' issues with medication costs, either time spent directly with patients or with third parties, such as pharmacies and payers. Sixty percent predicted a large timesaving impact (greater than eight on a 10 point scale). (Table 14a) While respondents gave the model resource high ratings on all its features, they found that the comparisons of prices of the same drugs at different pharmacies, as well as comparisons of the prices of brand name drugs and lower cost generic alternatives, to be most useful. (Table 9a , 9b, 9c) Almost half of the respondents (42.5 percent) thought it would be extremely important for the resource to include information on co-pays for ALL insurance plans, not just Medicare Part D, and 85 percent thought this additional feature would be at least moderately important. (Table 16 ) But even a resource with only Part D co-pay information would reportedly be used nearly as often as a resource with all insurance co-pay information. (Table 13) When asked what, if anything, they particularly disliked about the model drug pricing resource presented in Concept 1, a vast majority of respondents, 70 percent, answered "nothing." The most commonly voiced negative opinions were that it could be time-consuming (10 percent) and that it provided too much information (7.5 percent). (Table 10 ) Finally, half of the respondents thought it would be extremely important to have the resource available as an app for a mobile device (Table 17) , and 75 percent saw this as at least very important (seven or higher).
Discussion
Prescriber-patient communication about medication costs and impact on adherence
Primary care physicians surveyed in this study frequently encountered situations in which high out-of-pocket drug costs impacted adherence. In these circumstances, they reported that their patients either did not fill a prescription or took less than prescribed. Previous studies show that when patients cannot afford their medications, they may be unable to initiate or continue drug treatment, which can compromise quality of care and increase the patient's need for other, more expensive services, such as hospitalization [16] , [18] .
Because our sample of physicians only included those most interested in addressing the cost burden upon their patients, our findings understandably differ with broader surveys of providers in some respects. While all physicians in our pilot 
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study discussed drug costs with patients, a study of internists and patients regarding beliefs and experiences of medication use found that just 35 percent of physicians and 15 percent of patients had ever discussed costs, even though the need was clear, since one-third of patients reported being burdened by drug costs [2] . Similarly, a 2011 survey found that only 15 percent of the physician respondents had discussed out-ofpocket medication costs frequently with patients [24] . The results in our pilot study more closely match those of a study of provider communication with senior patients, a group with high health care and prescription drug needs, and lower than average incomes. In that study, nearly half of the physicians reported that they discussed costs with at least half their senior patients in the previous month [27] .
Studies do show, however, that a majority of doctors feel a professional obligation to both discuss drug affordability with their patients, and to consider costs when writing prescriptions [1] . Seventy-nine percent of the internists in the study cited above desired to discuss out-of-pocket costs with patients, while 91 percent of the physicians in the 2011 survey thought it was important to manage patient's out-ofpocket costs [24] .
If physicians report such a widespread sense of professional obligation to address costs with their patients, what are the barriers to such communication? Even among our respondents, half rated the difficulty of undertaking these discussions as six or higher on a 10 point scale. Earlier studies confirm that doctor-patient communication about medication costs is difficult and can be affected by many factors, including available information, relationships (e.g. trust, satisfaction, commitment), patient variation (e.g. attitudes, beliefs, condition, coverage), practitioner variation (e.g. attitudes, beliefs, expertise, practice organization) and role expectations (e.g. socially expected behavior in this prescribing process) [28] .
Reliable, accessible information on drug prices could address one of the above barriers to good communication and perhaps increase trust between patient and provider as well. A systematic review of 24 studies found that on the whole, physicians were not able to accurately estimate the cost of specific drugs. They also consistently underestimated the difference in prices between brand-name drugs and generics [29] . Not surprisingly, studies show that physician confidence in communicating about the costs of medications is influenced by their own level of knowledge of these costs. Physicians with higher perceived knowledge of drug costs were more likely to discuss costs with their patients. [27] Respondents reported using a number of strategies to lower costs for their patients, but some of these strategies may be counterproductive. For instance, drug samples that are widely distributed by the drug industry are designed to promote the newest, most expensive brand name drugs, and have been shown to increase patient out-of-pocket costs by 50 percent on average [26] . Brochures, flyers, coupons and vouchers provided by drug companies and sales representatives are also intended to market largely expensive brand-name drugs, which often compete with equally effective, low-cost generic drugs or lower-cost brand name drugs that treat the same conditions. Physicians in our survey spent a substantial amount of time each day (one hour on average) addressing issues related to medication costs. A common issue is handling requests from pharmacists, on behalf of patients filling a prescription, to change to a drug with a lower out-of-pocket cost. While it may take some time to use a pricing resource before making the initial prescribing decision, prescriber workload and effectiveness may be reduced if more affordable drugs were prescribed initially. For instance, a study of a tiered health plan found that patients who were initially prescribed generics or a lower cost brand name drug were less likely to switch medications later. Furthermore, the authors concluded that clinicians could improve medication adherence "by choosing wisely within a drug class and prescribing generic or preferred formulary agents when initiating chronic therapy" [15] .
While lack of affordability may discourage adherence to drug treatment recommendations, some patients may resist taking prescribed medicines for more fundamental reasons. A synthesis of qualitative studies of medicine-taking found that such resistance may occur not because of failings in patients, doctors or systems, but because of concerns patients have about taking medicines in general and about the safety and efficacy of medications that have previously been prescribed to them [29] . To address general patient concerns about medication, some have proposed that practitioners practice "minimally disruptive medicine" [31] , taking into account, for instance, that non-adherence may be the result of very high treatment burdens, especially among those with complex, chronic conditions. These burdens include multiple, usually uncoordinated providers, and multiple treatment guidelines and drug management policies for each chronic condition. We would suggest that high, cumulative out-of-pocket costs of multiple medications could be an important component of such treatment burdens, which prescribers would be better able to address if they had access to reliable, evidence-based information on medication options and their associated costs. 
INNOVATIONS in pharmacy
PRACTICE-BASED RESEARCH
Potential benefits to increased prescriber-patient engagement and practice efficiency
Our results suggest that a comprehensive, unbiased online resource on drug prices and therapeutic alternatives could improve the quality and efficiency of patient care. Foremost, such a price transparency resource could easily provide prescribers with transparent price information, which would (i) increase prescribers' comfort in initiating and engaging discussions of drug cost and affordability issues with their patients. In addition, such a resource would (ii) increase the staff efficiency in clinical settings, by freeing up time currently spent gathering price information, or dealing with pharmacist phone calls at the point of service.
Optimally, such a pricing resource would be most valuable to prescribers if it provided reliable, automatically updated, easily accessible information on drug prices and therapeutic alternatives, for use by prescribers or other providers, and consumers themselves. However, even less sophisticated approaches may provide substantial benefits. However, even less sophisticated approaches may provide substantial benefits. For instance, another pilot study using an educational module found that providing future prescribers with very general information on drug prices and therapeutic alternatives can have a measurable impact upon future prescribers' confidence in discussing cost and affordability with patients. [37] .
Broader implications for savings by the health care system
While further study of robust web-based pricing resources is necessary to predict the impact among providers and patients more broadly, it is likely that reducing the out-ofpocket cost burden for patients could also contribute to reducing total drugs costs for health plans, and our health care system overall. First, if lowering the out-of-pocket cost burden increases patient adherence, then other health care costs for hospitalization or acute care can be reduced. And within the drug market, brand-name drugs have higher copay costs, and higher total costs to health plans as well. The average difference in price between a brand and a generic was $76 per prescription in 2007, but brand and generic prices have polarized since then, with brands getting costlier, and generics getting cheaper. [38] In this context, reducing out-of-pocket costs by using more generic drugs can also produce significant savings for our health plans and health system overall.
Prior studies have shown this to be true. For instance, one study of an electronic prescribing system integrated with a clinical decision support system found a significant increase in evidence-based new prescriptions, and a reduction in the use of high-cost therapies. This resulted in savings of more than $850 per member per month in the first year. The system included both evidence-based therapeutic recommendations and cost comparisons. It did not use "forcing functions, popup windows or other features that directly interfered with the prescribing process or required action by the physician. It simply described the evidence (and costs) and let the physician decide" [33] . Notably, an electronic prescribing system without the decision support feature did not result in savings.
Conclusions
Our study indicates that when they occur, current prescriberpatient discussions about drug costs are time consuming, and even physicians who are concerned about the issue do not have these discussions with all of their patients, despite seeing non-adherence frequently each day. Studies of a broader cross-section of physicians have found that few discuss costs with their patients, but that most physicians and patients would like to address these issues.
Based on our pilot study, we suggest that comprehensive web-based drug pricing resources would have multiple benefits for both providers and their patients by fostering better patient-prescriber engagement, at the point of prescribing. Such a resource would provide providers with accurate price information for comparison between therapeutic options within any therapeutic class. Having ready access to this resource may give prescribers the confidence to initiate patient engagement, through communications about drug costs and affordability. Addressing a significant prescriber barrier prescriber-patient communication around affordability would likely have multiple benefits.
First, it could improve the doctor-patient relationship, by facilitating needed discussions about health care costs that support the doctor in engaging in prescribing decisions with awareness and sympathy for the cost burden faced by their patients. Second, it would help foster better prescriberpatient engagement and better shared decision-making, in the form of making a more effective initial prescribing decision. This could improve patient care, through prescription choices that would be less likely to be affected by cost-related non-adherence decisions by the patient. Finally, the resource may reduce prescriber and staff time spent investigating low-cost resources for patients, in addressing problems with patients who do not take their medications due to the cost, and in fielding pharmacy requests to prescribe cheaper medications after the initial prescription is written. Oringinal Research
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Given the interest among physicians in better engagement with patients on the issues of cost and affordability, and the current lack of comprehensive, reliable information on retail drug prices, our survey suggests that such web-based resources on drug pricing would be quickly adopted by physicians and other prescribers who are already engaged in addressing medication costs. Such resources also have the potential to be adopted more broadly, given the research showing widespread interest among physicians in discussing costs with patients in order to improve prescribing. [1] - [3] . After the Affordable Care Act is fully implemented in 2014, insurance coverage may expand significantly, but undocumented immigrants will undoubtedly continue to face barriers to subsidized insurance or Medicaid programs. In that context, providing a retail drug price transparency resource in Spanish and other languages may be necessary to help this particularly vulnerable population access affordable medication options.
Using such retail pricing resources would likely lower out-ofpocket costs for patients. In addition, accessible, unbiased information on therapeutic alternatives, including treatment profiles and side effects, would be of significant value to prescribers, and would be likely to promote health system savings overall. Including information on out-of-pocket copay costs under various insurance plans would make the resources still more effective and valuable.
There are few studies of patient barriers to communicating about drug cost burden to their providers, but ample evidence that those barriers exist, and could be adversely affecting the costs and quality of care that patients receive.
Further study of how price transparency resources could help patients in discussing issues of cost and affordability with their clinicians is needed.
APPENDIX A QUALITATIVE INTERVIEW GUIDE Patient/Provider Communications Regarding Prescription Prices
Medical Marketing Research, Inc. for Community Catalyst, 2012
Dr. Name _____________________________ Thank you, doctor for participating in our study. Today our interview will focus on the interaction and communication that occurs between patient and provider with regard to costs of medications prescribed. Your responses are considered confidential. There are no right or wrong answers; we are just seeking your candid thoughts and opinions on the issues we will be discussing.
For the sake of report development, we will be recording this interview. I will start the recorder now.
1. First of all, if you would briefly describe your practice (GROUP/SOLO, URBAN/RURAL, ETC.).
2. About what percent of your patients would you say are: Medicaid, Upper Income, Working Poor, Middle Class. 3. How do you know, learn of, patient's inability to pay or problems paying for prescriptions? How do you identify these patients, and when you do, how does it impact your prescribing? 4. And about what percent of your patients would you estimate have trouble paying for the prescription medications you prescribe? What kind of trouble -how often do you think they don't get their prescription filled at all? Get only part of their prescription filled? Don't take their medication as directed in order to reduce costs? What other behaviors have you noted patients engaging in to reduce medication costs? 5. Think for a moment of one of your patients who you knew had difficulty paying for their drugs. With that kind of person in mind, how might you communicate with them about the prices of medications and their ability to pay for them. Would you initiate the discussion, or wait for them to say something? Give me an example of how that discussion might go. 6. In general, how open are you to engaging in discussions with your patients on the cost of drugs, either their own ability to pay the out-of-pocket cost or the issue of the total costs as part of shared decision-making? 7. Do you use electronic information of any kind currently in your practice to interact with or advise patients? What do you use (PROBE FOR EXAMPLES). What about any kind of electronic pricing information concerning medications? 8. REFER TO SCREENSHOT OF WEBSITE: I want you to assume the availability of an electronic price data website (accessible via computer and by mobile device app) for you/your staff to use in discussions with patients about prescriptions and pharmacy location choices. Assume that the site would be quick and easy to use; could be used by yourself, your staff, and/or your patients; would contain pricing information on virtually every product you might prescribe, list over 90% of pharmacies within a given ZIP code, and would offer:  Comparisons by pharmacy of the same generic or brand name drugs; price comparisons of generics vs. their brand name equivalents; and information about low cost therapeutic alternatives to brand names that do not have exact generic (E.g. omeprazole as an alternative to Nexium)  Availability of price comparisons by drug at all or most pharmacies in the patient's zip code area, along with mail order services  Availability of information on insurance plans (E.g. formularies and co-pay tiers) 9. What specific barriers do you see to the use of such a tool, even with the desired functionalities? What additional features would make it most useful -probe integration with e-prescribing, integration with other electronic systems? How interested would you be in using such a resource? 
The difference between the price of brand-name drugs and lower cost generic alternatives?
The differences in exact prices for the same drug at different pharmacies? Respondents spend more than an hour a day addressing cost-related issues, including discussions with 43% (13 of 30) of their patients, on average. Exact price differences between pharmacies was rated as rather useful (8, 9, 10) by three fourths of all respondents, with a third of respondents (35%) rating it as high as possible. 
